Reviva Pharmaceuticals Holdings, Inc. (RVPHW)

US — Healthcare Sector
Peers: RVPH  ATNFW  CLNNW  LIXTW  ARTLW 

Automate Your Wheel Strategy on RVPHW

With Tiblio's Option Bot, you can configure your own wheel strategy including RVPHW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol RVPHW
  • Rev/Share 0.0
  • Book/Share 0.0245
  • PB 27.4946
  • Debt/Equity 0.5638
  • CurrentRatio 1.0056
  • ROIC -22.6654

 

  • MktCap 31502760.0
  • FreeCF/Share -1.012
  • PFCF -0.9391
  • PE -0.7467
  • Debt/Assets 0.0296
  • DivYield 0
  • ROE 7.2282

 

  • Rating
  • Score
  • Recommendation
  • P/E Score
  • DCF Score
  • P/B Score
  • D/E Score

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Reviva Pharmaceuticals Holdings, Inc. (RVPHW)

  • IPO Date
  • Website https://www.revivapharma.com
  • Industry Biotechnology
  • CEO Dr. Laxminarayan Bhat Ph.D.
  • Employees 14
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California.